Posts

UCB Acquires Neurona Therapeutics for Up to $1.15B to Advance Epilepsy Cell Therapy

on

Xenon Pharmaceuticals' Azetukalner Achieves Phase 3 Success in Epilepsy Trial, Boosting Blockbuster Potential

on

Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration

on

Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data

on

Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219

on

Expert Flags Potential 'Honeymoon Effect' as Rapport Heads Towards Phase III Epilepsy Trials

on

Epiminder Appoints Mark McLellan as Chief Financial Officer

on

Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

on

Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial

on

Praxis touts 'best-in-disease' epilepsy data, but shares dip

on

Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

on

Neurona nabs $102M to launch pivotal trial of epilepsy cell therapy

on

Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

on

Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment

on